Skip to main content

Table 1 Patient characteristics

From: Expansion of antibody secreting cells and modulation of neutralizing antibody activity in HIV infected individuals undergoing structured treatment interruptions

Patient Id Age (years) Sexa Years since diagnosis Baseline VLc(RNA copies/ml) Baseline CD4 cell count (cells/mm3) Baseline CD8 cell count (cells/mm3) Baseline treatmentb IL-2 administration
1 42 F 5 80 1327 1225 D4T + 3TC + NFV NO
2 54 M 12 33 801 763 D4T + 3TC + NFV NO
3 39 M 2 50 580 548 DDI + 3TC + NFV NO
4 34 M 15 1200 672 819 ABV + DDI + EFV NO
5 41 F 8 20 2702 1061 3TC + NFV + AZT NO
6 45 F 7 20 1548 1380 DDI + D4T + NFV YES
7 51 F 16 20 956 697 D4T + IDV + 3TC + RTV YES
8 55 M 4 20 801 744 D4T,3TC,NFV YES
9 61 M 5 20 1122 570 IDV + 3TC + AZT YES
10 51 M 9 20 987 810 EFV + D4T + 3TC YES
  1. aM: male; F: female.
  2. bD4T: Stavudine; 3TC:Lamivudine; NFV: Nelfinavir; DDI: Didanosine; ABV: Abacavir; EFV: Efavirenz; AZT: Zidovudina; IDV: Indinavir; RTV: Ritonavir.
  3. c In patient 4 VL value at baseline of 1200 correspond to a blip in viral load as, both prior and post values are < 20.